Jan. 20 at 5:06 PM
$TIVC An update from Tivic Health Systems ( ) is now available.
On January 20, 2026, , Inc. announced it had made an investor presentation available on its website, outlining a clinical pipeline centered on its TLR5 agonist portfolio, led by Entolimod in late Phase III development for acute radiation syndromes and Entolasta in pre-clinical development for chronic radiation syndromes. The presentation highlights more than
$140 million in prior investment, over 40 human and animal studies, extensive patent protection, and development funding from U.S. government agencies that are now positioned as key customer prospects, positioning Tivic to compete in the fast-growing global market for hematopoietic and gastrointestinal radiation treatments—currently dominated by G-CSF-based drugs and projected to reach
$21.3 billion by 2032—while signaling multiple anticipated near-term value inflection points for stakeholders as the company advances its oncology and medical
